Data from the Australian National Diabetes Audit (ANDA) showed that in 2019, 27% of people with T2DM were on an SGLT2 inhibitor and 12% were on a GLP1 receptor agonist [35]. Here, SLC5A2 is linked to type 2 diabetes mellitus.